key: cord-0692044-155t8kcy
authors: Walter, Jeanette; Kricheldorf, Kim; Isfort, Susanne; Brümmendorf, Tim H.; Panse, Jens; Beier, Fabian
title: Antibody titers after SARS‐CoV‐2 mRNA vaccination in patients with aplastic anemia—A single‐center study
date: 2022-02-28
journal: Eur J Haematol
DOI: 10.1111/ejh.13756
sha: 5da687173aef530c51e8494483ce515564162481
doc_id: 692044
cord_uid: 155t8kcy

nan

Letter to the editor, In 2020, the SARS-CoV-2 virus spread all over the world also affecting patients with hematologic diseases. 1 Patients with aplastic anemia (AA) were thought to be at particular risk for severe or fatal courses of COVID-19 due to cytopenias caused by the underlying disease as well as through their immunosuppressive treatment regimens. 1 We initiated a retrospective analysis of post-vaccination antibody levels and blood counts in patients with AA or AA/PNH overlap syndrome.

Sixteen patients (8 female/8 male, median age 57.5 years, range 24-69 years) were identified with sufficient data within the Aachen Registry for Telomeropathies and Aplastic Syndromes. 6 Written informed consent for the registry was obtained according to the approval by the local ethic committee EK (332/20).

All patients are currently undergoing immunosuppressive treatment including ATG and CSA and/or additional treatments with Eltrombopag or C5-complement inhibitors at the University Hospital of RWTH Aachen. All patients treated with ATG received horse ATG (ATGAM ® ). Details about treatments including time intervals between diagnosis, ATG application, and first vaccination are shown in Table 1 We did not observe further correlations of treatment modalities and antibody levels.

Since antibody levels against the SARS-CoV-2 spike protein are known to rapidly decrease within the first weeks after second vaccinations in healthy individuals, 7 we stratified our patients antibody titers in a cross-sectional approach according to the time after second vaccination. Here, we found a continuous decline in antibody levels from a median of 848 BAU/ml (range 176-1040 BAU/ml) after the 1st month to 410 BAU/ml (range 168-1040 BAU/ml) in the 2nd month and to 367 BAU/ml (range 223-936 BAU/ml) after 3 to 6 months after the second vaccination ( Figure 1A ). Antibody levels were comparable to those recently published in a large cohort of health care workers with mean antibody levels of 760, 688, and 501 BAU/ml after 1, 2, and 3 months, respectively. 7 Our observation of declining antibody levels was further confirmed in six patients where individual follow-up measurements of the vaccination levels were available. Here, all patients except for one (patient #10, Table 1 ) showed declining antibody levels over time ( Figure 1B ). Of note, third vaccinations resulted in adequate and rapid increase in the antibody levels >1040 BAU/ml in four of our patients with available follow-up data ( Figure 1C ).

Recent reports showed a possible relationship between vaccination and relapse or de novo AA. 8, 9 All patients within this cohort, showed stable blood counts in all three linages after any of the vaccinations given during follow-up, except for patient #10 who developed two episodes of isolated, self-limiting mild neutropenia after the first and second vaccination ( Figure 1D , compare patient #10, Table 1 

We provide first data on the vaccination titers against SARS-CoV-2 in patients with aplastic anemia.

Vaccination titers in AA patients undergoing immunosuppression show dynamics comparable to healthy individuals and third vaccination results in adequate and sufficient antibody response. No relapse or relevant changes in blood counts were observed after vaccination. Patients vaccinated after ATG show a modest antibody response.

Our data indicate that immunosuppression in AA patients does not affect development of antibody levels comparable to healthy individuals without evidence for relapse or changes in blood counts. AA patients can be vaccinated within the first weeks after ATG treatment. 

We thank all patients and families for the support and for participating in this study.

The other authors have nothing to disclose.

FB and JW conceived and planned the study design, interpreted the data, and wrote the manuscript. SI and KK supported the study and interpreted the data. SI, THB, and JP analyzed the data, planned the study design, and revised the manuscript.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. F I G U R E 1 Vaccination response in AA and AA/PNH patients after second SARS-CoV-2 vaccination. (A) SARS-CoV-2 spike protein IgG titers in BAU/ml of 16 patients with AA or AA/PNH overlap syndrome measured 1, 2, or 3 to 6 months after second SARS-CoV-2 vaccination (red line =median, whiskers =25% or 75% percentiles). Plot of individual patient follow-up of the SARS-CoV-2 spike protein IgG titers [BAU/ml] 1 to 7 months after second SARS-CoV-2 vaccination before (B) and after (C) third vaccination ("booster"). Time point of the third vaccination is indicated by the red arrows. (B: compare patient numbers #4, #5, #9, #10, #12, and #15. C: compare patient numbers #3, #4, #9, and #15, see Table 1 ) (D) Blood counts of neutrophils, hemoglobin values, and platelets after two vaccinations with BNT162b2 in patient #10

COVID-19 in benign hematology: Emerging challenges and special considerations for healthcare professionals

Are patients with autoimmune cytopenias at higher risk of COVID-19 Pneumonia? The experience of a reference center in Northern Italy and review of the literature

COVID-19 -bone marrow failure and PNH: Recommendations on behalf of the severe aplastic Anemia working party. European Group for Blood and Marrow Transplantation (EBMT)

Covid-19 breakthrough infections in vaccinated health care workers

COVID-19 vaccines

Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines

Severe aplastic anemia after COVID-19 mRNA vaccination: Causality or coincidence?

COVID-19 infection in patients with severe aplastic anaemia

WHO. Interim statement on booster doses for COVID-19 vaccination